Immutep Limited (NASDAQ:IMMP - Get Free Report) shares crossed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $2.28 and traded as low as $1.91. Immutep shares last traded at $1.95, with a volume of 48,963 shares trading hands.
Wall Street Analyst Weigh In
Separately, Robert W. Baird dropped their price target on Immutep from $7.00 to $6.00 and set an "outperform" rating on the stock in a research report on Thursday, June 27th.
Get Our Latest Analysis on Immutep
Immutep Stock Performance
The business's 50-day moving average is $2.28 and its 200-day moving average is $2.40.
Hedge Funds Weigh In On Immutep
Several large investors have recently made changes to their positions in IMMP. XTX Topco Ltd bought a new position in Immutep during the 2nd quarter valued at approximately $26,000. BNP Paribas Financial Markets increased its holdings in shares of Immutep by 15.4% during the first quarter. BNP Paribas Financial Markets now owns 35,300 shares of the biotechnology company's stock valued at $82,000 after acquiring an additional 4,700 shares in the last quarter. XY Capital Ltd purchased a new position in shares of Immutep in the 2nd quarter worth about $105,000. Virtu Financial LLC boosted its stake in Immutep by 269.4% in the 1st quarter. Virtu Financial LLC now owns 45,062 shares of the biotechnology company's stock worth $105,000 after purchasing an additional 32,864 shares in the last quarter. Finally, Oracle Investment Management Inc. grew its position in Immutep by 9.4% during the 1st quarter. Oracle Investment Management Inc. now owns 564,879 shares of the biotechnology company's stock valued at $1,316,000 after purchasing an additional 48,449 shares during the last quarter. 2.32% of the stock is currently owned by hedge funds and other institutional investors.
About Immutep
(
Get Free Report)
Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.
Featured Articles
Before you consider Immutep, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immutep wasn't on the list.
While Immutep currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
